{"id":"NCT02735044","sponsor":"Sanofi","briefTitle":"Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus","officialTitle":"6-Month, Multicenter, Randomized, Open-label, 2-Arm, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Injected Once Daily in Children and Adolescents Age 6 - 17 Years With Type 1 Diabetes Mellitus With a 6-month Safety Extension Period","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-04-14","primaryCompletion":"2018-05-31","completion":"2018-12-20","firstPosted":"2016-04-12","resultsPosted":"2019-06-19","lastUpdate":"2022-03-25"},"enrollment":463,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 1 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Insulin glargine,300 U/mL","otherNames":["Toujeo ®"]},{"type":"DRUG","name":"Insulin glargine (100 units /mL)","otherNames":[]},{"type":"DRUG","name":"Background therapy","otherNames":[]}],"arms":[{"label":"HOE901-U300","type":"EXPERIMENTAL"},{"label":"Lantus","type":"ACTIVE_COMPARATOR"}],"summary":"Primary Objective:\n\nTo compare the efficacy of a new formulation of insulin glargine (HOE901-U300) to Lantus in terms of change of HbA1c from baseline to endpoint (month 6) in children and adolescents with type 1 diabetes mellitus.\n\n.\n\nSecondary Objectives:\n\nTo compare HOE901-U300 and Lantus in terms of:\n\n* Percentage of participants reaching target HbA1c and fasting plasma glucose (FPG).\n* To assess the safety of HOE901-U300 including analysis of events of hypoglycemia, events of hyperglycemia with ketosis, and development of anti-insulin-antibodies.","primaryOutcome":{"measure":"Change From Baseline in HbA1c to Month 6","timeFrame":"Baseline to Month 6","effectByArm":[{"arm":"HOE901-U300","deltaMin":-0.399,"sd":0.063},{"arm":"Lantus","deltaMin":-0.402,"sd":0.064}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":"0.965"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":12},"locations":{"siteCount":107,"countries":["United States","Argentina","Brazil","Bulgaria","Canada","Chile","Czechia","Denmark","France","Germany","Hungary","Israel","Italy","Japan","Latvia","Mexico","North Macedonia","Poland","Romania","Russia","Serbia","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["32430458"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":35,"n":233},"commonTop":["Nasopharyngitis","Ketosis","Upper Respiratory Tract Infection","Pharyngitis","Headache"]}}